BRPI0403935A - Formas de dosagem de azitromicina com efeitos colaterais reduzidos - Google Patents
Formas de dosagem de azitromicina com efeitos colaterais reduzidosInfo
- Publication number
- BRPI0403935A BRPI0403935A BR0403935-1A BRPI0403935A BRPI0403935A BR PI0403935 A BRPI0403935 A BR PI0403935A BR PI0403935 A BRPI0403935 A BR PI0403935A BR PI0403935 A BRPI0403935 A BR PI0403935A
- Authority
- BR
- Brazil
- Prior art keywords
- azithromycin
- glyceryl
- oral dosage
- effective amount
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
"FORMAS DE DOSAGEM DE AZITROMICINA COM EFEITOS COLATERAIS REDUZIDOS". Uma forma de dosagem oral compreendendo azitromicina e um quantidade eficaz de um agente de alcalinização. Preferivelmente, a referida forma de dosagem oral compreende uma quantidade eficaz de um agente de alcalinização e um multiparticulado de azitromicina onde o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. Tipicamente, a forma de dosagem oral inclui quaisquer métodos de dosagem oral adequados tal como um pó para suspensão oral, uma embalagem ou sachê de dose única, um comprimido ou uma cápsula. Adicionalmente é descrita uma suspensão oral compreendendo azitromicina, uma quantidade eficaz de um agente de alcalinização e um veículo. Preferivelmente, a azitromicina é em forma de multiparticulado em que o referido multiparticulado compreende azitromicina, uma mistura de monobeenato de glicerila, dibeenato de glicerila e tribeenato de glicerila, e um poloxâmero. é também descrito um método para reduzir efeitos colaterais gastrointestinais, associados com administração de azitromicina a um mamífero, compreendendo administrar contiguamente azitromicina e uma quantidade eficaz de agente de alcalinização ao referido mamífero em que a freq³ência de efeitos colaterais gastrointestinais é menor do que aquela experimentada administrando-se uma dose igual de azitromicina sem o referido agente de alcalinização. Além disso é descrito um método de tratar uma infecção bacteriana ou protozoária em um mamífero em necessidade deste compreendendo administrar contiguamente ao referido mamífero uma dose única de uma forma de dosagem oral em que a referida forma de dosagem oral compreende azitromicina e uma quantidade eficaz de um agente de alcalinização. Adicionalmente são descritos multiparticulados de azitromicina compreendendo azitromicina, um tensoativo; e um veículo farmaceuticamente aceitável.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52708403P | 2003-12-04 | 2003-12-04 | |
US60/527,084 | 2003-12-04 | ||
US10/763,340 | 2004-01-23 | ||
US10/763,340 US6984403B2 (en) | 2003-12-04 | 2004-01-23 | Azithromycin dosage forms with reduced side effects |
PCT/IB2004/001654 WO2005053650A1 (en) | 2003-12-04 | 2004-05-14 | Azithromycin dosage forms with reduced side effects |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0403935A true BRPI0403935A (pt) | 2005-08-09 |
BRPI0403935B1 BRPI0403935B1 (pt) | 2018-02-06 |
BRPI0403935B8 BRPI0403935B8 (pt) | 2021-05-25 |
Family
ID=34468055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0403935A BRPI0403935B8 (pt) | 2003-12-04 | 2004-05-14 | formas de dosagem de azitromicina com efeitos colaterais reduzidos |
Country Status (36)
Country | Link |
---|---|
US (4) | US6984403B2 (pt) |
EP (1) | EP1537859B1 (pt) |
JP (2) | JP4602711B2 (pt) |
KR (1) | KR100906290B1 (pt) |
AR (1) | AR045630A1 (pt) |
AT (1) | ATE407663T1 (pt) |
BR (1) | BRPI0403935B8 (pt) |
CA (1) | CA2467611C (pt) |
CL (1) | CL2004001501A1 (pt) |
CR (1) | CR7500A (pt) |
CY (1) | CY1108486T1 (pt) |
DE (1) | DE602004016444D1 (pt) |
DK (1) | DK1537859T3 (pt) |
DO (1) | DOP2004000994A (pt) |
EA (1) | EA010110B1 (pt) |
ES (1) | ES2312929T3 (pt) |
GE (1) | GEP20074056B (pt) |
HK (1) | HK1080367B (pt) |
HR (1) | HRP20040865A2 (pt) |
IL (1) | IL164165A (pt) |
IS (1) | IS2672B (pt) |
MA (1) | MA27848A1 (pt) |
MX (1) | MXPA04009424A (pt) |
NL (1) | NL1026315C2 (pt) |
NO (1) | NO20043903L (pt) |
NZ (1) | NZ535464A (pt) |
OA (1) | OA12858A (pt) |
PA (1) | PA8611501A1 (pt) |
PE (1) | PE20050573A1 (pt) |
PL (2) | PL1537859T3 (pt) |
PT (1) | PT1537859E (pt) |
RS (1) | RS84704A (pt) |
SI (1) | SI1537859T1 (pt) |
TW (1) | TWI351969B (pt) |
UY (1) | UY28509A1 (pt) |
WO (1) | WO2005053650A1 (pt) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1096862C (zh) † | 1994-05-06 | 2002-12-25 | 辉瑞大药厂 | 阿齐霉素的控释剂型 |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
DK2368554T3 (en) * | 2003-04-08 | 2015-01-26 | Progenics Pharm Inc | A pharmaceutical composition comprising methylnaltrexone |
WO2005053652A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
ATE399536T1 (de) * | 2003-12-04 | 2008-07-15 | Pfizer Prod Inc | Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten |
US8236349B2 (en) * | 2004-04-12 | 2012-08-07 | Bend Research Inc. | Taste-masked drugs in rupturing multiparticulates |
PT1765292T (pt) | 2004-06-12 | 2017-12-29 | Collegium Pharmaceutical Inc | Formulações de fármacos dissuasoras de abuso |
WO2006004085A1 (ja) | 2004-07-02 | 2006-01-12 | Wakamoto Pharmaceutical Co., Ltd. | アジスロマイシン含有水性医薬組成物及びその調製方法 |
JP4713104B2 (ja) * | 2004-08-04 | 2011-06-29 | ファイザー株式会社 | アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物 |
US20060193908A1 (en) * | 2004-11-09 | 2006-08-31 | Burnside Beth A | Extended release formulations of poorly soluble antibiotics |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (es) * | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
US20060252831A1 (en) * | 2005-05-06 | 2006-11-09 | Christopher Offen | Method for the treatment of magnesium and potassium deficiencies |
US20060252830A1 (en) * | 2005-05-06 | 2006-11-09 | Brandon Stephen F | Method for the treatment of magnesium and potassium deficiencies |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
SG2014009252A (en) * | 2005-12-22 | 2014-05-29 | Otsuka Pharma Co Ltd | Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol |
CN101340882B (zh) * | 2005-12-22 | 2015-02-11 | 大塚制药株式会社 | 含有药物的蜡基质粒子的制造方法、用于该方法的挤出机、及含有西洛他唑的缓释制剂 |
WO2007143507A2 (en) * | 2006-06-05 | 2007-12-13 | Auspex Pharmaceuticals, Inc. | Preparation and utility of substituted erythromycin analogs |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
US11116728B2 (en) | 2006-11-30 | 2021-09-14 | Bend Research, Inc. | Multiparticulates of spray-coated drug and polymer on a meltable core |
EP2091519B1 (en) * | 2006-11-30 | 2015-06-24 | Bend Research, Inc | Multiparticulates of spray-coated drug and polymer on a meltable core |
JP5162134B2 (ja) * | 2007-01-22 | 2013-03-13 | 愛媛県 | 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品 |
JP5452236B2 (ja) * | 2007-03-02 | 2014-03-26 | ファーナム・カンパニーズ・インコーポレーテッド | ロウ様物質を用いた徐放性組成物 |
SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
CN101801979A (zh) | 2007-03-29 | 2010-08-11 | 普罗热尼奇制药公司 | (r)-n-溴化甲基纳曲酮的晶体形式及其用途 |
CA2865661C (en) | 2007-03-29 | 2016-05-17 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
DE102007026550A1 (de) * | 2007-06-08 | 2008-12-11 | Bayer Healthcare Ag | Extrudate mit verbesserter Geschmacksmaskierung |
DE102007034155A1 (de) * | 2007-07-21 | 2009-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Vorrichtung mit mindestens einer Verpackungseinheit mit einem zur Radiofrequenz-Identifikation dienenden RFID-Chip und Verfahren dazu |
CN101959429B (zh) | 2008-01-08 | 2014-09-10 | 阿克塞利亚制药公司 | 抗微生物肽系统的激动剂 |
JP5358587B2 (ja) | 2008-02-06 | 2013-12-04 | プロジェニックス・ファーマシューティカルス・インコーポレイテッド | (r),(r)−2,2’−ビス−メチルナルトレキソンの製造及び用途 |
CA2719134C (en) * | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
JP5839189B2 (ja) * | 2008-07-21 | 2016-01-06 | オトノミ—,インク. | 耳の不調の治療用の制御放出性の抗菌性組成物および方法 |
CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
EP2314286A1 (de) * | 2009-10-21 | 2011-04-27 | Ratiopharm GmbH | Schmelzgranuliertes Cinacalcet |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2011125075A2 (en) | 2010-04-08 | 2011-10-13 | Fdc Limited | A novel gastroretentive delivery of macrolide |
EP3246287A1 (en) | 2011-02-11 | 2017-11-22 | ZS Pharma, Inc | Microporous zirconium silicate for the treatment of hyperkalemia |
ES2841809T3 (es) | 2011-06-03 | 2021-07-09 | Eisai R&D Man Co Ltd | Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
US9943637B2 (en) | 2012-06-11 | 2018-04-17 | ZS Pharma, Inc. | Microporous zirconium silicate and its method of production |
CN104968336A (zh) | 2012-07-11 | 2015-10-07 | Zs制药公司 | 用于治疗高钙血症患者高钾血症的微孔硅酸锆以及用于治疗高钾血症的改进的含钙组合物 |
JP6423795B2 (ja) | 2012-10-22 | 2018-11-14 | ズィーエス・ファーマ,インコーポレーテッド | 高カリウム血症を治療するための微多孔性ケイ酸ジルコニウム |
US10695365B2 (en) | 2012-10-22 | 2020-06-30 | ZS Pharma, Inc. | Microporous zirconium silicate for the treatment of hyperkalemia |
CA2933048A1 (en) * | 2013-12-10 | 2015-06-18 | ZS Pharma, Inc. | Zirconium silicate for treating hyperkalemia without co-administering lithium |
ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
HUE064614T2 (hu) | 2015-02-25 | 2024-04-28 | Eisai R&D Man Co Ltd | Eljárás egy kinolin-származék keserû ízének elnyomására |
CA2978322A1 (en) * | 2015-03-10 | 2016-09-15 | Lumos Pharma, Inc. | Cyclocreatine microsuspension |
CA2988575C (en) | 2015-06-10 | 2024-04-16 | Piedmont Animal Health, Llc | Injectable antibiotic formulations and use thereof |
AU2016279474B2 (en) | 2015-06-16 | 2021-09-09 | Eisai R&D Management Co., Ltd. | Anticancer agent |
SI3429559T1 (sl) | 2016-03-15 | 2022-11-30 | Acer Therapeutics Inc. | Okusni sestavki, ki vključujejo natrijev fenilbutirat, in njihove uporabe |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
WO2018141063A1 (en) * | 2017-02-02 | 2018-08-09 | Mcmaster University | Bicarbonate as a potentiator for antimicrobial agents |
EP3829640A4 (en) | 2018-08-01 | 2022-05-25 | McMaster University | METHOD OF INHIBITING MICROBIAL GROWTH |
CN111643455A (zh) * | 2020-06-22 | 2020-09-11 | 健民药业集团股份有限公司 | 一种阿奇霉素缓释干混悬剂及其制备方法 |
WO2022220669A1 (es) * | 2021-04-16 | 2022-10-20 | Garcia Perez Miguel Angel | Combinación sólida oral para el tratamiento de infección por virus |
CN114699386B (zh) * | 2022-04-14 | 2023-05-23 | 深圳职业技术学院 | 阿奇霉素组合物及其制备方法 |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US26851A (en) * | 1860-01-17 | Improvement | ||
US25342A (en) * | 1859-09-06 | Justus k | ||
US228357A (en) * | 1880-06-01 | Walter m | ||
US6650A (en) * | 1849-08-14 | Edmund blunt | ||
US3590A (en) * | 1844-05-17 | Rule or measure | ||
US190365A (en) * | 1877-05-01 | Improvement in running-gear for vehicles | ||
US165563A (en) * | 1875-07-13 | Improvement in snow-plows | ||
US14951A (en) * | 1856-05-27 | Boot-tree | ||
US2955956A (en) | 1957-05-15 | 1960-10-11 | Morton Salt Co | Process and apparatus for coating granules |
US4086346A (en) | 1974-04-06 | 1978-04-25 | Bayer Aktiengesellschaft | Preparation of melt-sprayed spherical phenacetin granules |
US4092089A (en) | 1974-04-06 | 1978-05-30 | Bayer Aktiengesellschaft | Apparatus for the preparation of melt-sprayed spherical phenacetin granules |
US4053264A (en) | 1976-01-30 | 1977-10-11 | United Technologies Corporation | Apparatus for making metal powder |
US4293570A (en) | 1979-04-02 | 1981-10-06 | Chimicasa Gmbh | Process for the preparation of sweetener containing product |
SI8110592A8 (en) | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
US4474768A (en) | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
KR920006865B1 (ko) | 1984-05-18 | 1992-08-21 | 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 | 입자나 액적을 피복하는 방법과 장치 |
US4874611A (en) | 1985-06-20 | 1989-10-17 | The Dow Chemical Company | Microencapsulated ant bait |
US5100592A (en) | 1986-03-12 | 1992-03-31 | Washington University Technology Associated, Inc. | Method and apparatus for granulation and granulated product |
US5019302A (en) | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
US5456932A (en) | 1987-04-20 | 1995-10-10 | Fuisz Technologies Ltd. | Method of converting a feedstock to a shearform product and product thereof |
US5236734A (en) | 1987-04-20 | 1993-08-17 | Fuisz Technologies Ltd. | Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix |
US5387431A (en) | 1991-10-25 | 1995-02-07 | Fuisz Technologies Ltd. | Saccharide-based matrix |
RU2066324C1 (ru) | 1987-07-09 | 1996-09-10 | Пфайзер Инк. | Кристаллический дигидрат азитромицина и способ его получения |
WO1989002271A1 (en) | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
HRP20020231A2 (en) * | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
DE3812567A1 (de) | 1988-04-15 | 1989-10-26 | Basf Ag | Verfahren zur herstellung pharmazeutischer mischungen |
US5064650A (en) | 1988-04-19 | 1991-11-12 | Southwest Research Institute | Controlled-release salt sensitive capsule for oral use and adhesive system |
US5160743A (en) | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US4931285A (en) | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5024842A (en) | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5047244A (en) | 1988-06-03 | 1991-09-10 | Watson Laboratories, Inc. | Mucoadhesive carrier for delivery of therapeutical agent |
US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
JPH03206039A (ja) * | 1990-01-08 | 1991-09-09 | Kyoto Yakuhin Kogyo Kk | ニフェジピン持続性製剤 |
US5084287A (en) | 1990-03-15 | 1992-01-28 | Warner-Lambert Company | Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat |
US5213810A (en) | 1990-03-30 | 1993-05-25 | American Cyanamid Company | Stable compositions for parenteral administration and method of making same |
EP0452862B1 (en) | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
US5183690A (en) | 1990-06-25 | 1993-02-02 | The United States Of America, As Represented By The Secretary Of Agriculture | Starch encapsulation of biologically active agents by a continuous process |
GB9014646D0 (en) | 1990-07-02 | 1990-08-22 | Courtaulds Coatings Holdings | Coating compositions |
US5194262A (en) | 1990-10-22 | 1993-03-16 | Revlon Consumer Products Corporation | Encapsulated antiperspirant salts and deodorant/antiperspirants |
US5196199A (en) | 1990-12-14 | 1993-03-23 | Fuisz Technologies Ltd. | Hydrophilic form of perfluoro compounds and method of manufacture |
US5292657A (en) | 1990-12-31 | 1994-03-08 | Pioneer Hi-Bred International, Inc. | Process for preparing rotary disc fatty acid microspheres of microorganisms |
US5143662A (en) | 1991-02-12 | 1992-09-01 | United States Surgical Corporation | Process for preparing particles of bioabsorbable polymer |
US5707546A (en) * | 1991-06-17 | 1998-01-13 | Rio Linda Chemical Co., Inc. | Generation and storage of chlorine dioxide in a non-aqueous medium |
US5405617A (en) | 1991-11-07 | 1995-04-11 | Mcneil-Ppc, Inc. | Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals |
GB9201857D0 (en) | 1992-01-29 | 1992-03-18 | Smithkline Beecham Plc | Novel compound |
JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
DE4214272A1 (de) | 1992-05-04 | 1993-11-11 | Nukem Gmbh | Verfahren und Vorrichtung zur Herstellung von Mikrokugeln |
CA2095776C (en) | 1992-05-12 | 2007-07-10 | Richard C. Fuisz | Rapidly dispersable compositions containing polydextrose |
DK0641195T3 (da) | 1992-05-22 | 1996-08-05 | Goedecke Ag | Fremgangsmåde til fremstilling af lægemiddelblandinger med forsinket virkning |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
TW271400B (pt) | 1992-07-30 | 1996-03-01 | Pfizer | |
US5348758A (en) | 1992-10-20 | 1994-09-20 | Fuisz Technologies Ltd. | Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material |
US5380473A (en) | 1992-10-23 | 1995-01-10 | Fuisz Technologies Ltd. | Process for making shearform matrix |
GB9224855D0 (en) | 1992-11-27 | 1993-01-13 | Smithkline Beecham Plc | Pharmaceutical compositions |
US5569467A (en) | 1993-05-15 | 1996-10-29 | Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) | Process for the preparation of microballs and microballs thus obtained |
US5690959A (en) | 1993-05-29 | 1997-11-25 | Smithkline Beecham Corporation | Pharmaceutical thermal infusion process |
US5851553A (en) | 1993-09-10 | 1998-12-22 | Fuisz Technologies, Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5597416A (en) | 1993-10-07 | 1997-01-28 | Fuisz Technologies Ltd. | Method of making crystalline sugar and products resulting therefrom |
US5935600A (en) | 1993-09-10 | 1999-08-10 | Fuisz Technologies Ltd. | Process for forming chewable quickly dispersing comestible unit and product therefrom |
US5433951A (en) | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
AT401871B (de) | 1994-01-28 | 1996-12-27 | Gebro Broschek Gmbh | Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung |
GB9402203D0 (en) * | 1994-02-04 | 1994-03-30 | Smithkline Beecham Plc | Pharmaceutical formulation |
ES2270426T3 (es) | 1994-03-18 | 2007-04-01 | Supernus Pharmaceuticals, Inc. | Sistema de suministros de farmacos emulsionados. |
US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
CN1096862C (zh) * | 1994-05-06 | 2002-12-25 | 辉瑞大药厂 | 阿齐霉素的控释剂型 |
DE19509807A1 (de) | 1995-03-21 | 1996-09-26 | Basf Ag | Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5582855A (en) | 1994-07-01 | 1996-12-10 | Fuisz Technologies Ltd. | Flash flow formed solloid delivery systems |
US5556652A (en) | 1994-08-05 | 1996-09-17 | Fuisz Technologies Ltd. | Comestibles containing stabilized highly odorous flavor component delivery systems |
US5601761A (en) | 1994-09-26 | 1997-02-11 | The Dow Chemical Company | Encapsulated active materials and method for preparing same |
US5493044A (en) * | 1994-10-20 | 1996-02-20 | Fmc Corporation | Process for preparing alkylsilyl or arylsilyl ethers |
US5965164A (en) | 1994-10-28 | 1999-10-12 | Fuisz Technologies Ltd. | Recipient-dosage delivery system |
US5683720A (en) | 1994-10-28 | 1997-11-04 | Fuisz Technologies Ltd. | Liquiflash particles and method of making same |
US6083430A (en) | 1994-10-28 | 2000-07-04 | Fuisz Technologies Ltd. | Method of preparing a dosage unit by direct tableting and product therefrom |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
FR2732621B1 (fr) | 1995-04-10 | 1997-06-06 | Rhone Poulenc Chimie | Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention |
US5972373A (en) | 1995-05-02 | 1999-10-26 | Taisho Pharmaceutical Co., Ltd. | Taste masking pharmaceutical composition for oral administration |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US5883103A (en) | 1995-06-07 | 1999-03-16 | Shire Laboratories Inc. | Oral acyclovir delivery |
WO1997002019A1 (en) | 1995-06-30 | 1997-01-23 | Baylor University | Polyester/carboxylic acid composite materials |
EP0784933A3 (en) | 1995-10-16 | 1997-11-26 | Leaf, Inc. | Extended release of additives in comestible products |
US5919489A (en) | 1995-11-01 | 1999-07-06 | Abbott Laboratories | Process for aqueous granulation of clarithromycin |
US5705190A (en) | 1995-12-19 | 1998-01-06 | Abbott Laboratories | Controlled release formulation for poorly soluble basic drugs |
US5916582A (en) * | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
DE19629753A1 (de) | 1996-07-23 | 1998-01-29 | Basf Ag | Verfahren zur Herstellung von festen Arzneiformen |
US6139872A (en) | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
TW474824B (en) | 1996-09-13 | 2002-02-01 | Basf Ag | The production of solid pharmaceutical forms |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
DE19652257A1 (de) * | 1996-12-16 | 1998-06-18 | Lohmann Therapie Syst Lts | Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform |
US5948407A (en) | 1997-03-19 | 1999-09-07 | Shire Laboratories Inc. | Oral induction of tolerance to parenterally administered non-autologous polypeptides |
US6010718A (en) | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6551616B1 (en) * | 1997-04-11 | 2003-04-22 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
US6656508B2 (en) * | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
DE19729487A1 (de) | 1997-07-10 | 1999-01-14 | Dresden Arzneimittel | Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix |
SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
US5851555A (en) | 1997-08-15 | 1998-12-22 | Fuisz Technologies Ltd. | Controlled release dosage forms containing water soluble drugs |
US5869098A (en) | 1997-08-20 | 1999-02-09 | Fuisz Technologies Ltd. | Fast-dissolving comestible units formed under high-speed/high-pressure conditions |
US5840334A (en) | 1997-08-20 | 1998-11-24 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
US5980941A (en) | 1997-08-20 | 1999-11-09 | Fuisz Technologies Ltd. | Self-binding shearform compositions |
IT1294760B1 (it) * | 1997-09-03 | 1999-04-12 | Jagotec Ag | Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco |
AU9496798A (en) * | 1997-09-19 | 1999-04-05 | Shire Laboratories, Inc. | Solid solution beadlet |
IE970731A1 (en) | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
US6013280A (en) | 1997-10-07 | 2000-01-11 | Fuisz Technologies Ltd. | Immediate release dosage forms containing microspheres |
US6096340A (en) | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US5891845A (en) | 1997-11-21 | 1999-04-06 | Fuisz Technologies Ltd. | Drug delivery systems utilizing liquid crystal structures |
WO1999029299A1 (en) * | 1997-12-08 | 1999-06-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Novel suppository form comprising an acid-labile active compound |
US6270804B1 (en) | 1998-04-03 | 2001-08-07 | Biovail Technologies Ltd. | Sachet formulations |
US6423345B2 (en) * | 1998-04-30 | 2002-07-23 | Acusphere, Inc. | Matrices formed of polymer and hydrophobic compounds for use in drug delivery |
JPH11335300A (ja) * | 1998-05-20 | 1999-12-07 | Sumitomo Pharmaceut Co Ltd | グリセリン脂肪酸エステルを使用した徐放性製剤 |
FR2779651B1 (fr) * | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
US6086920A (en) | 1998-08-12 | 2000-07-11 | Fuisz Technologies Ltd. | Disintegratable microspheres |
US6117452A (en) | 1998-08-12 | 2000-09-12 | Fuisz Technologies Ltd. | Fatty ester combinations |
CA2245398C (en) | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
US6165512A (en) | 1998-10-30 | 2000-12-26 | Fuisz Technologies Ltd. | Dosage forms containing taste masked active agents |
JP2002531409A (ja) * | 1998-11-30 | 2002-09-24 | テバ ファーマシューティカル インダストリーズ リミティド | アジスロマイシンのエタノール付加物、その製造方法、及びその医薬製剤 |
DE19901683B4 (de) * | 1999-01-18 | 2005-07-21 | Grünenthal GmbH | Analgetikum mit kontrollierter Wirkstofffreisetzung |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
EP1027888B1 (en) * | 1999-02-10 | 2009-06-10 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6291013B1 (en) * | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
WO2001022937A1 (en) * | 1999-09-27 | 2001-04-05 | Sonus Pharmaceuticals, Inc. | Compositions of tocol-soluble therapeutics |
IL141438A0 (en) * | 2000-02-23 | 2002-03-10 | Pfizer Prod Inc | Method of increasing the bioavailability and tissue penetration of azithromycin |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
PL371125A1 (en) * | 2001-12-21 | 2005-06-13 | Pfizer Products Inc. | Methods for wet granulating azithromycin |
EP1455758A1 (en) * | 2001-12-21 | 2004-09-15 | Pfizer Products Inc. | Directly compressible formulations of azithromycin |
NZ534234A (en) * | 2002-02-01 | 2007-05-31 | Pfizer Prod Inc | Dry granulated formulations of non-dihydrate form of azithromycin |
US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20040121003A1 (en) * | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
ATE421882T1 (de) * | 2003-07-24 | 2009-02-15 | Pliva Hrvatska D O O | Schnellösliches azithromycin in einzeldosisform |
-
2004
- 2004-01-23 US US10/763,340 patent/US6984403B2/en not_active Expired - Lifetime
- 2004-05-06 ES ES04252643T patent/ES2312929T3/es not_active Expired - Lifetime
- 2004-05-06 SI SI200430865T patent/SI1537859T1/sl unknown
- 2004-05-06 DE DE602004016444T patent/DE602004016444D1/de not_active Expired - Lifetime
- 2004-05-06 AT AT04252643T patent/ATE407663T1/de active
- 2004-05-06 DK DK04252643T patent/DK1537859T3/da active
- 2004-05-06 PT PT04252643T patent/PT1537859E/pt unknown
- 2004-05-06 EP EP04252643A patent/EP1537859B1/en not_active Expired - Lifetime
- 2004-05-06 PL PL04252643T patent/PL1537859T3/pl unknown
- 2004-05-14 BR BRPI0403935A patent/BRPI0403935B8/pt active IP Right Grant
- 2004-05-14 NZ NZ535464A patent/NZ535464A/en unknown
- 2004-05-14 GE GEAP8414A patent/GEP20074056B/en unknown
- 2004-05-14 PL PL379984A patent/PL379984A1/pl not_active Application Discontinuation
- 2004-05-14 OA OA1200400253A patent/OA12858A/en unknown
- 2004-05-14 RS YUP-847/04A patent/RS84704A/sr unknown
- 2004-05-14 EA EA200401216A patent/EA010110B1/ru not_active IP Right Cessation
- 2004-05-14 MX MXPA04009424A patent/MXPA04009424A/es active IP Right Grant
- 2004-05-14 WO PCT/IB2004/001654 patent/WO2005053650A1/en active Application Filing
- 2004-05-18 CA CA2467611A patent/CA2467611C/en not_active Expired - Lifetime
- 2004-06-02 NL NL1026315A patent/NL1026315C2/nl not_active IP Right Cessation
- 2004-06-04 TW TW093116207A patent/TWI351969B/zh active
- 2004-06-16 CL CL200401501A patent/CL2004001501A1/es unknown
- 2004-08-04 JP JP2004228455A patent/JP4602711B2/ja active Active
- 2004-09-07 PE PE2004000861A patent/PE20050573A1/es not_active Application Discontinuation
- 2004-09-08 PA PA20048611501A patent/PA8611501A1/es unknown
- 2004-09-09 DO DO2004P000994A patent/DOP2004000994A/es unknown
- 2004-09-10 AR ARP040103256A patent/AR045630A1/es not_active Application Discontinuation
- 2004-09-13 UY UY28509A patent/UY28509A1/es not_active Application Discontinuation
- 2004-09-17 NO NO20043903A patent/NO20043903L/no not_active Application Discontinuation
- 2004-09-20 HR HR20040865A patent/HRP20040865A2/hr not_active Application Discontinuation
- 2004-09-20 IS IS7464A patent/IS2672B/is unknown
- 2004-09-20 IL IL164165A patent/IL164165A/en active IP Right Grant
- 2004-09-29 CR CR7500A patent/CR7500A/es unknown
- 2004-10-11 KR KR1020047016213A patent/KR100906290B1/ko active IP Right Grant
-
2005
- 2005-08-25 US US11/212,433 patent/US20060029677A1/en not_active Abandoned
- 2005-10-26 US US11/259,839 patent/US20060039988A1/en not_active Abandoned
- 2005-12-08 MA MA28638A patent/MA27848A1/fr unknown
-
2006
- 2006-01-05 HK HK06100226.0A patent/HK1080367B/zh not_active IP Right Cessation
-
2007
- 2007-07-18 US US11/779,489 patent/US20080015343A1/en not_active Abandoned
-
2008
- 2008-11-06 CY CY20081101264T patent/CY1108486T1/el unknown
-
2010
- 2010-03-01 JP JP2010044743A patent/JP2010132700A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0403935A (pt) | Formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
HRP20180237T4 (hr) | Metode za liječenje hcv-a | |
TW200630123A (en) | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form | |
HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
JP2016518387A5 (pt) | ||
BRPI0408999A (pt) | comprimidos prensados de multiparticulados de liberação oral prolongada | |
RS20090083A (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta -mimetics | |
WO2012079092A3 (en) | Testosterone undecanoate compositions | |
MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
MX344476B (es) | Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal. | |
WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
RU2010126327A (ru) | Композиция на основе пробиотических бактерий совместно с пребиотиком и ее применение в предупреждении и/или лечении респираторных патологий и/или инфекций и для улучшения функций кишечника | |
RU2009133447A (ru) | Дозированная форма пикоплатина | |
RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
GB2456475A (en) | Composition for the treatment of skin conditions | |
GEP20043285B (en) | Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections | |
CA2595363A1 (en) | Methods and materials with trans-clomiphene for the treatment of male infertility | |
AP2218A (en) | Azithromycin dosage forms with reduced side effects | |
JPWO2021099783A5 (pt) | ||
WO2003105811A8 (en) | PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE | |
MD3381G2 (ro) | Metodă de tratament al parotiditei cronice la copii | |
JP2005519919A5 (pt) | ||
SE0002354D0 (sv) | New formulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA: INT. CL. A61K 9/16; A61P 31/00 Ipc: A61K 9/16 (2011.01), A61P 31/00 (2011.01) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |